Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 34.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 200,269 shares of the medical equipment provider's stock after selling 107,194 shares during the period. Handelsbanken Fonder AB owned about 0.10% of Zimmer Biomet worth $21,619,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in ZBH. Price T Rowe Associates Inc. MD raised its position in shares of Zimmer Biomet by 12.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,642,801 shares of the medical equipment provider's stock worth $1,404,638,000 after purchasing an additional 1,215,935 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Zimmer Biomet by 12.6% in the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider's stock valued at $701,521,000 after acquiring an additional 722,041 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Zimmer Biomet by 6.7% in the second quarter. Victory Capital Management Inc. now owns 3,364,624 shares of the medical equipment provider's stock worth $365,163,000 after acquiring an additional 211,637 shares during the last quarter. Van ECK Associates Corp boosted its stake in Zimmer Biomet by 5.3% during the 2nd quarter. Van ECK Associates Corp now owns 3,325,598 shares of the medical equipment provider's stock worth $360,927,000 after purchasing an additional 167,038 shares during the last quarter. Finally, Boston Partners grew its stake in Zimmer Biomet by 26.3% during the 1st quarter. Boston Partners now owns 3,314,939 shares of the medical equipment provider's stock valued at $437,413,000 after acquiring an additional 691,191 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of research reports. Oppenheimer dropped their price objective on Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating for the company in a research note on Thursday, August 8th. Morgan Stanley decreased their price objective on Zimmer Biomet from $130.00 to $120.00 and set an "equal weight" rating for the company in a research note on Monday, July 15th. Evercore ISI cut their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating on the stock in a research note on Tuesday, October 1st. Truist Financial reiterated a "hold" rating and issued a $112.00 price target (down previously from $117.00) on shares of Zimmer Biomet in a research note on Friday, September 13th. Finally, Piper Sandler downgraded shares of Zimmer Biomet from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $140.00 to $115.00 in a research report on Monday, July 1st. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $125.05.

Zimmer Biomet Trading Down 1.4 %

Shares of Zimmer Biomet stock traded down $1.47 during trading hours on Monday, reaching $103.21. The stock had a trading volume of 345,357 shares, compared to its average volume of 1,491,654. The firm has a market capitalization of $21.23 billion, a price-to-earnings ratio of 22.50, a P/E/G ratio of 1.94 and a beta of 1.02. The company has a current ratio of 1.29, a quick ratio of 0.63 and a debt-to-equity ratio of 0.31. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $133.90. The firm has a 50 day simple moving average of $109.19 and a two-hundred day simple moving average of $113.98.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, beating the consensus estimate of $1.99 by $0.02. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The firm's revenue was up 3.9% compared to the same quarter last year. During the same period last year, the company posted $1.82 earnings per share. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.93%. The ex-dividend date of this dividend is Monday, September 30th. Zimmer Biomet's dividend payout ratio (DPR) is 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.